Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Shares Outstanding (2009 - 2025)

Grifols' (GIFLF) quarterly Shares Outstanding (Entity) came in at $680.5 million in Q4 2025, little changed on a YoY basis from $679.7 million in Q4 2024, and little changed quarter-over-quarter from $679.7 million in Q4 2024.

Analysis

Grifols (GIFLF) Shares Outstanding (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Shares Outstanding (Entity) for 17 consecutive years, with $680.5 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Entity) changed 0.12% year-over-year to $680.5 million; the trailing twelve-month figure through Dec 2025 stood at $680.5 million (changed 0.12% YoY), and the FY2025 full-year result was $680.5 million, changed 0.12% from the prior year.
  • Shares Outstanding (Entity) steadied at $680.5 million in Q4 2025 per GIFLF's latest filing, from $679.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Entity) topped out at $681.6 million in Q4 2021 and bottomed at $679.7 million in Q4 2024.
  • Historically, Shares Outstanding (Entity) has averaged $680.3 million across 5 years, with a median of $679.8 million in 2022.
  • The sharpest annual moves came in 2021 and 2025: Shares Outstanding (Entity) dropped 0.58% in 2021, then increased 0.12% in 2025.
  • Over 5 years, Shares Outstanding (Entity) stood at $681.6 million in 2021, then decreased by 0.26% to $679.8 million in 2022, then retreated by 0.01% to $679.8 million in 2023, then dropped by 0.01% to $679.7 million in 2024, then climbed by 0.12% to $680.5 million in 2025.
  • According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $680.5 million, $679.7 million, and $679.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Outstanding (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 540.00 Mn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 1.24 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 253.70 Mn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 102.80 Mn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 61.30 Mn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 398.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 133.61 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 147.70 Mn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 720.78 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 680.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 680.51 Mn
Dec 31, 2024 679.67 Mn
Dec 31, 2023 679.76 Mn
Dec 31, 2022 679.81 Mn
Dec 31, 2021 681.56 Mn
Dec 31, 2020 685.52 Mn
Sep 30, 2020 685.12 Mn
Mar 31, 2020 685.12 Mn
Dec 31, 2019 685.12 Mn
Sep 30, 2019 684.71 Mn
Mar 31, 2019 684.71 Mn
Dec 31, 2018 684.71 Mn
Sep 30, 2018 684.20 Mn
Jun 30, 2018 684.20 Mn
Mar 31, 2018 684.20 Mn
Dec 31, 2017 684.20 Mn
Jun 30, 2017 683.23 Mn
Mar 31, 2017 683.23 Mn
Dec 31, 2016 683.23 Mn
Sep 30, 2016 683.55 Mn